The Efficacy and Safety of Propiverine Hydrochloride in Patients with Overactive Bladder Symptoms Who Poorly Responded to Previous Anticholinergic Agents by Masumori, Naoya et al.
Hindawi Publishing Corporation
Advances in Urology
Volume 2011, Article ID 714978, 4 pages
doi:10.1155/2011/714978
Clinical Study
TheEfﬁcacyandSafety ofPropiverineHydrochloride
in Patients with Overactive Bladder Symptoms Who Poorly
Respondedto Previous AnticholinergicAgents
Naoya Masumori,1 ShintaroMiyamoto,1 Taiji Tsukamoto,1 SeijiFuruya,2 AkihikoIwasawa,3
Takashi Sato,4 Naoki Itoh,5 Akihiko Shibuya,6 andToshiroOda7
1Department of Urology, Sapporo Medical University School of Medicine, Sapporo 060-8543, Japan
2Furuya Hospital, Urology service, Kitami 090-0065, Japan
3Iwasawa Clinic, Urology service, Sapporo 060-0061, Japan
4Nisshin Urological Clinic, Urology service, Tomakomai 053-0833, Japan
5NTT East Japan Sapporo Hospital, Division of Urology, Sapporo 060-0061, Japan
6Kaguraoka Urological Clinic, Urology service, Asahikawa 078-8315, Japan
7Kiyota Urological Clinic, Urology service, Sapporo 004-0841, Japan
Correspondence should be addressed to Naoya Masumori, masumori@sapmed.ac.jp
Received 19 April 2011; Accepted 5 May 2011
Academic Editor: Yasuhiko Igawa
Copyright © 2011 Naoya Masumori et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
Objectives.Toprospectivelyexaminetheeﬃcacyandsafetyofpropiverinehydrochlorideinpatientswithoveractivebladder(OAB)
symptoms who poorly responded to previous treatment with solifenacin, tolterodine or imidafenacin. Methods. Patients aged ≥20
with persisting OAB symptoms (≥6 in OAB symptom score (OABSS)) even after at least 4-week treatment using solifenacin,
tolterodine or imidafenacin were enrolled. Propiverine 20 mg/day was administered for 12 weeks to 70 patients who desired the
further improvement of OAB symptoms and 3 who had intolerable adverse events of previous drugs. The OABSS and postvoid
residualurinevolume(PVR)weredeterminedbeforeandat4and12weeksoftreatment. Results.Of73patientsenrolled(29males
and 44 females, median age 71 years), 52 completed the protocol treatment. The OABSS was signiﬁcantly improved by propiverine
treatment(9.0atbaseline,6.2at4weeks,6.3at12weeks(P<0.001)).ThescoresofOABsymptoms(nighttimefrequency,urgency
andurgeincontinence)exceptdaytimefrequencyalsoimprovedsigniﬁcantly.NoincreaseinPVRwasobserved.Themostfrequent
adverse event was dry mouth (13.7%), followed by constipation (6.8%). Conclusions. Propiverine is useful to improve OAB for
patients who poorly respond to solifenacin, tolterodine or imidafenacin.
1.Introduction
Overactive bladder (OAB), a syndrome that presents urinary
urgency as an essential symptom [1] ,h a sag r e a ti m p a c to n
the quality of life (QOL) of the patient. A nationwide survey
conducted in Japan [2] demonstrated that the estimated
prevalence of OAB was 12.4% in the general population over
age 40. The study showed that 11.2% and 53.0% of subjects
with OAB reported “an impact” and “a slight impact”
on their QOL by OAB symptoms, respectively, through
the impairment of mental health, vitality, physical activity,
domestic work, and business work. Since the actual number
of patients with OAB has been increasing in parallel with
the advancement of aging society, the appropriate treatment
strategy should be established immediately.
Drugswithanticholinergicactivityaretheﬁrst-linedrugs
to treat OAB symptoms [3]. Propiverine hydrochloride is
an agent with calcium antagonistic activity in addition
to anticholinergic activity [4]. A double-blind randomized
control study demonstrated that propiverine was superior
to oxybutynin hydrochloride in terms of the improvement
of pollakisuria and urinary incontinence associated with
neurogenicbladderandunstablebladder[5].Sinceitslaunch
in 1993, propiverine hydrochloride has been widely used2 Advances in Urology
in clinical settings in Japan. On the other hand, three
new anticholinergic agents, solifenacin succinate, tolterodine
tartrate, and imidafenacin, were successively approved and
marketed in recent years. Diﬀerent from propiverine, these
drugs have no calcium antagonistic activity. Diﬀerences in
clinical eﬃcacy remain unknown between propiverine with
calcium antagonistic activity and new anticholinergic agents
without the activity. In the present study, we examined the
clinical eﬃcacy and safety of propiverine for patients with
OABsymptomswhopoorlyrespondedtoprevioustreatment
with solifenacin, tolterodine, or imidafenacin.
2. Methods
The present study was conducted in patients aged ≥20 who
had ≥6pointsinoveractivebladdersymptomscore(OABSS)
[6] even after at least 4-week treatment with solifenacin,
tolterodine, or imidafenacin. Of them, 70 patients who
desired the further improvement of OAB symptoms and
3 patients who desired to change previous anticholinergic
drugs because of their adverse events were enrolled in the
study. Propiverine 20mgq.d. was administered for 12 weeks.
Subjective symptoms and objective ﬁndings were assessed by
the OABSS and determination of PVR, respectively, before
and at 4 and 12 weeks of treatment. Information of adverse
events reported during the treatment period was collected.
Paired t-test was performed to examine changes in the
OBASS and PVR. A combined analysis model was used
to investigate diﬀerences in therapeutic eﬀects by previous
anticholinergic agent and by gender.
The present study was approved by the institutional
review board at Sapporo Medical University (no. 19–48)
and performed at 19 institutions as a multi-institutional
study between January 2008 and December 2009. Written
informed consent was obtained from all participants.
3. Results
Twenty-nine men and 44 women were enrolled in the study.
M e d i a na g eo f7 3p a t i e n t sw a s7 1y e a r s .N od i ﬀerence was
observed in age (mean ± standard deviation) between men
(72.6±11.2y e a r s )a n dw o m e n( 7 0 .2±11.4y e a r s ,P = 0.38).
Regarding previous anticholinergic agents, 34, 14, and 25
patients received a standard dose of solifenacin, tolterodine,
and imidafenacin, respectively. These agents were given for
<8 weeks in 22 (30.1%), 8–12 weeks in 11 (15.1%), and ≥12
weeks in 40 (54.8%) patients. Of the 29 men, 15 (51.2%)
had received an α1-adrenoceptor antagonist at the entry. The
drug was continued without change in the dosage during the
study period.
Of 73 subjects, 52 (71.2%) completed the protocol treat-
ment and 21 (28.8%) withdrew from the study. The main
reasons of discontinuation were “no visit to the hospital” in
9 and “adverse events” in 7, followed by “withdrawal of the
consent” in 2 and deterioration of comorbid diseases in 2.
Of 52 subjects who completed the protocol treatment,
the OABSS improved signiﬁcantly at 4 and 12 weeks of
propiverine treatment (Table 1). Among OAB symptoms,
nighttime frequency, urgency, and urgency incontinence
Table 1 :C h a n g e si no v e r a c t i v eb l a d d e rs y m p t o ms c o r e si n5 2
patients treated with propiverine hydrochloride.
Baseline 4 weeks 12 weeks
OABSS 9.0 ±2.2(1) 6.2 ± 3.3∗∗ 6.3 ±3.3∗∗
Daytime frequency 0.9 ±0.40 .8 ±0.60 .8 ±0.4
Nighttime frequency 2.3 ±0.81 .9 ±0.8∗ 1.9 ±0.9∗∗
Urgency 3.7 ±0.92 .3 ± 1.7∗∗ 2.2 ±1.6∗∗
Urgency incontinence 2.2 ±1.61 .2 ± 1.6∗∗ 1.4 ±1.6∗
OABSS: overactive bladder symptom score.
(1)Mean ± standard deviation.
∗P<0.01, ∗∗P<0.001 (versus baseline, paired t-test).
except daytime frequency showed signiﬁcant improvements
by propiverine treatment. The eﬃcacy of propiverine was
analyzed according to previous anticholinergic agent and
to gender (Table 2). Regardless of the type of previous
anticholinergicagents,theOABSSimprovedsigniﬁcantly.No
signiﬁcant diﬀerence in OABSS change was observed among
the previous drugs (P = 0.31). Although the OABSS was
signiﬁcantlyimproved bypropiverine treatmentinboth men
and women, propiverine was less eﬀective in men than in
women (P<0.01).
The eﬀects of propiverine on PVR were analyzed in 50
subjects who completed the protocol treatment and whose
PVR was measured. PVRs (mean ± standard deviation) were
31 ±41,32±43(P = 0.76),and32±42mL(P = 0.81)before
and at 4 and 12 weeks of treatment, respectively. PVRs did
not increase signiﬁcantly both in men (n = 19) and women
(n = 31) at 4 and 12 weeks of propiverine treatment.
The overall incidence of adverse events was 21.9%
(16/73), and all were mild and moderate in intensity
(Table 3). Dry mouth was the most frequently reported
adverse event in 13.7% (10/73), followed by constipation
in 6.8% (5/73). Seven patients discontinued the protocol
treatment due to adverse events (dry mouth in 4, urinary
retention in 1, gastric distress in 1, and anorexia in 1).
Urinary retention was developed in a 70-year-old woman 78
days after administration. All adverse events except anorexia
were recovered by discontinuation of the drug.
4. Discussion
Propiverine hydrochloride inhibits abnormal contractions
of bladder smooth muscle in vivo through not only its
anticholinergic activity but also its concurrent calcium
antagonistic activity [7]. Calcium antagonistic activity has
not been reported with other anticholinergic agents such
as solifenacin, tolterodine, and imidafenacin. Although both
cholinergic and atropine-resistant contractions are involved
in the development of unstable bladder [8], elderly patients
with OAB are likely to show the increased involvement
of atropine-resistant contractions that poorly respond to
anticholinergic agents. Propiverine that signiﬁcantly inhibits
atropine-resistant contractions through the calcium antag-
onistic activity [9] may be useful for patients with OAB
who show the increased involvement of atropine-resistant
contractions.Advances in Urology 3
Table 2: Changes in overactive bladder symptoms by previous anticholinergic agent and by gender.
Variables Overactive bladder symptom scores
Baseline 4 weeks 12 weeks P-value(2)
Solifenacin (n = 27) 9.4 ±2.5(1) 7.2 ±3.9∗∗ 6.5 ±3.9∗∗
P = 0.31 Tolterodine (n = 10) 8.4 ±1.44 .7 ±1.7∗∗ 5.9 ±2.5∗
Imidafenacin (n = 15) 8.7 ±2.15 .4 ±2.2∗∗ 6.1 ±2.8∗∗
Male (n = 21) 8.5 ±1.96 .9 ±3.2∗∗ 6.4 ±2.9∗∗
P<0.01
Female (n = 31) 9.4 ±2.45 .7 ±3.3∗∗ 6.1 ±3.6∗∗
(1)Mean ± standard deviation.
(2)Comparison among groups (combined analysis model).
∗P<0.01, ∗∗P<0.001 (versus baseline, paired t-test).
Table 3: Adverse events in 73 patients.
Adverse events n (%) Mild Moderate Severe Serious
Dry mouth 10 (13.7) 6 4 0 0
Constipation 5 (6.8) 5 0 0 0
Urinary retention 1 (1.4%) 0 1 0 0
Blurred vision 1 (1.4%) 1 0 0 0
Urinary tract infection1 (1.4%) 1 0 0 0
Gastric distress 1 (1.4%) 0 1 0 0
Anorexia 1 (1.4%) 0 1 0 0
Mild: no impairment of activity of daily life.
Moderate: limited activity of daily life.
Serve: impossible activity of daily life.
Serious: life-threatening.
In real-world clinical practice, an anticholinergic agent
with insuﬃcient eﬃcacy is often switched to another anti-
cholinergic agent. However, this modality has not been
clearly proven yet. In the present study, propiverine signiﬁ-
cantly improved the OABSS in poor responders to previous
treatment with solifenacin, tolterodine, or imidafenacin. We
speculate that the calcium antagonistic activity which is
speciﬁc to propiverine allowed the drug to exert eﬃcacy also
in patients who had shown the insuﬃcient eﬃcacy of other
anticholinergic agents without the activity.
In the present study, a signiﬁcant gender diﬀerence was
found in the eﬃcacy of propiverine. Although the reasons
why the eﬃcacy of propiverine appeared more rapidly in
women than in men remain unknown, diﬀerences in the
etiology of OAB or pharmacokinetics/pharmacodynamics
between men and women may be involved. This is a topic
to be investigated in the future because gender diﬀerence has
never been studied.
Anticholinergic agents are known to develop systemic
adverse reactions such as dry mouth, constipation, and
impairment of eye accommodation. Propiverine is a drug
that is nonselective to muscarinic receptor subtypes. In
a treatment outcome survey conducted in approximately
10,000 patients in Japan, the safety of propiverine was
veriﬁed [10].Althoughtheincidencesofdrymouthandcon-
stipation in the present study were 13.7% and 6.8%, respec-
tively, the values were equivalent to those in previous studies.
Inthepresentstudy,9(42.9%)of21patientswhodiscon-
tinued the protocol treatment never visited the hospital. The
previoussurvey[10]demonstratedthatthemajorreasonsfor
treatment discontinuation were “symptom improvement”
and “no visit to the hospital.” Tanaka and Masumori [11]
also reported that the improvement of symptoms was a
major reason of termination in 21 (68%) of 31 patients who
discontinued propiverine treatment. Thus, OAB symptoms
were likely to be improved by the short-term intake of
propiverine in some patients, which made them never come
back to the hospital.
Since this study did not conduct as a double-blind
placebo-controlled trial, the placebo eﬀect may be involved
insymptomatic improvement.Inaddition, theimprovement
may be obtained even by switching among solifenacin,
tolterodine, and imidafenacin [12–14]. However, to date,
no eﬃcient therapeutic strategy has been established in
patients who poorly responded to treatment with anti-
cholinergic agents, because of the lack of well-designed
placebo-controlled trials. The observation that propiverine
was eﬀective for poor responders to other anticholinergic
agents is of great clinical relevance. Therefore, propiverine
is considered as one of options for a second-line treatment
even if the eﬃcacy of solifenacin, tolterodine, or imidafe-
nacin is insuﬃcient, although the placebo-controlled trial is
deﬁnitely necessary to prove it.
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